Creative Biolabs provides various gastrointestinal diseases rodent models involving the stomach, small intestine, and the liver for novel drug discovery and development. Our scientific team has extensive experience helping our clients with the selection of appropriate models and assays, as well as collaborating to design new models to meet the specific needs of a particular compound or discovery program.
Ethanol is reported to cause gastric damage via decreased mucus production and blood circulation within the mucosa, generation of reactive species, decreased cell proliferation, and an exacerbated inflammatory response. As a result, ethanol-induced gastric mucosal ulceration is a useful model to investigate the details of the pathogenic mechanisms as well as to discover new anti-ulcer agents. To study the anti-ulcer effect of potential drug agents, various assessments are available at Creative Biolabs, including the measurement of ulcerated area, detection of gastric wall mucus secretion, and histological analysis.
Administration of carbon tetrachloride (CCl4) to rodents is a widely used model to study liver pathologies, which shows similar morphology and the biochemical characteristic of the cellular lesions with human liver diseases. A single dose of CCl4 leads to centrizonal necrosis and steatosis, while prolonged administration leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). We provide a wide range of assessments for evaluation of potential new therapeutics using both acute and chronic CCl4-induced hepatic injury models.
Hapten-induced colitis models are induced by rectal instillation of the mucosal sensitizing agents: dinitrobenzene sulfonic acid (DNBS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS), diluted in varying concentrations of ethanol. These models have the advantages of low cost, a rapid development of colitis, and consistent localized damage to the distal colon. Compared to DNBS, TNBS is considered as a preferred choice of chemical to induce colitis due to its highly oxidative properties.
Dextran sodium sulfate (DSS) is a water-soluble, negatively charged sulfated polysaccharide that can be used to induce a form of mouse colitis that mimics the clinical and histological features of Ulcerative Colitis (UC). We provide acute, chronic and relapsing models induced with different concentrations of DSS and varied administration frequencies. They are widely used for UC research due to their rapidity, simplicity, reproducibility, and controllability. Assessments such as body weight, gastrointestinal permeability, histological analysis can be performed.
As a commonly used nonsteroidal drug to decrease the fever, pain and other effect caused by inflammation, indomethacin is widely used to induce small intestine injury in rat models. These models are characterized by increased mucosal permeability, infiltration of neutrophils, upregulation of inflammatory cytokines and small-intestinal lesions, sharing many similarities with human Crohn's disease (CD), suggesting that they are appropriate models for new drug investigations. In assessing the efficacy of potential therapeutics, various measurements can be performed at Creative Biolabs, such as mucosal permeability, intestinal inflammation, cytokine production, and histopathologic analysis.
Oxazolone is a chemical allergen and a haptenating agent that is widely used to induce Th2-mediated colitis. This model has exhibited similar histologic features and distribution of inflammation to UC, which has important implications for the use of this model in the study of the pathogenesis and treatment of UC.
Hepatitis B virus (HBV) is a noncytopathic, enveloped virus with a circular, double-stranded DNA genome. The infection of HBV will result in acute or chronic necroinflammatory liver diseases. Moreover, chronic HBV infection is the major cause of hepatic cirrhosis and hepatocellular carcinoma (HCC), leading to high death rates. For the development of therapies of established infections of HBV, Creative Biolabs utilizes several effective rodent HBV models for the therapeutic evaluation of drug candidates, including:
In addition to the validated models described above, Creative Biolabs offers customized solutions by working with our clients to develop novel models for disease areas that may not be readily or easily standardized in the field. If you're interested in our services, please contact us to discuss your specific requirements.
For lab research use only.